Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 42Ovarian Neoplasms 33Fallopian Tube Neoplasms 15Neoplasms 12Carcinoma, Ovarian Epithelial 10Uterine Cervical Neoplasms 7Recurrence 6Neuroblastoma 5Lung Neoplasms 5Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Sarcoma, Ewing 3Endometrial Neoplasms 3Uterine Cervical Dysplasia 2Sarcoma, Clear Cell 2Sarcoma 2Rhabdomyosarcoma 2Myoepithelioma 2Medulloblastoma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Hereditary Sensory and Autonomic Neuropathies 2Diffuse Intrinsic Pontine Glioma 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Carcinoma 2Solid Tumours 1Solid Tumors 1Solid Tumor 1SCLC 1

Interventions

Fulvestrant 9Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3Cetuximab 3sapanisertib 2pembrolizumab 2parsaclisib 2binimetinib 2Topotecan 2NVP-BKM120 2Irinotecan 2Gemcitabine 2venetoclax 1tipifarnib 1talazoparib 1sotorasib 1ruxolitinib 1olaparib 1obinutuzumab 1niraparib 1lorlatinib 1liposomal doxorubicin 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × Topotecan × Clear all
NCT05246111 2024-11-22

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
6 enrolled 30 charts

Hereditary Sensory and Autonomic Neuropathies

NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

EMD Serono

Phase 2 Completed
76 enrolled 42 charts
Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡